IDEAYA BIOSCIENCES INC

IDEAYA Biosciences (IDYA) is a clinical-stage biotechnology company focused on precision oncology, notably exploiting synthetic lethality to develop targeted cancer therapies. With a market capitalisation of about $2.56B, IDEAYA advances small molecules alongside biomarker strategies to identify patients most likely to benefit. The company is mainly pipeline-driven: value depends on clinical trial progress, regulatory milestones and partnership agreements rather than steady revenues. That profile brings both significant upside if trials succeed and pronounced downside if they do not — typical of early- to mid-stage biotechs. Investors should expect volatility, potential future fundraising or dilution, and long development timelines. This summary is general educational information only and not personal investment advice; investors should weigh clinical, regulatory and financial risks and consider suitability for their own risk tolerance before considering any position.